摘要
大剂量化疗 (HDC)加干细胞移植在非霍奇金淋巴瘤 (NHL)治疗中的应用日益广泛 ,大量临床试验已证实其疗效。但对 HDC在 NHL各种亚型中的应用、最佳的移植时机以及移植方式等仍有颇多争论。 HDC现已成为化疗敏感的复发病例的标准治疗 ,而作为缓解后巩固治疗 ,则适用于高危患者。目前 ,异体移植仅限于某些特殊病例 ,其作用仍有待进一步研究。
High dose chemotherapy(HDC) with stem cell transplantion(SCT) has been used widely to treat non Hodgkin's lymphoma(HHL). Its curative effect has been confirmed by many trials.But controversy still exists,such as application of HDC for various NHL subtypes,the optimum opportunity and method for transplantation. HDC has become standard therapy for recuring cases which are sensitive to chemotherapy and was a suitable consolidation therapy after remission for high risk cases. Allogenic bone marrow marrow transplantation,only used for some special cases,need further study.
出处
《医学研究生学报》
CAS
2001年第2期157-161,共5页
Journal of Medical Postgraduates
关键词
非何杰金淋巴瘤
大剂量化疗
干细胞移植
治疗
non Hodgkin's lymphoma
Highdose chemotherapy
Stem cell transplantation
